Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)

Fig. 4

miR-1297 is an upstream regulatory miRNA for ADM A TargetScan, miRDB, miRanda, mirDIP, and Starbase were used to predict miRNAs that might target ADM; cross-checked results were compared with miRNAs downregulated in tumor samples. B The expression levels of four candidates were examined in normal non-cancerous samples (n = 18), stage I + II glioma samples (n = 8), and stage III + IV glioma samples (n = 10) using qRT-PCR. C The expression levels of four candidates were examined in a normal human glial cell line SVG p12 and a glioma cell line LN-229 using qRT-PCR. D miR-1297 overexpression or inhibition was achieved in LN-229 cells by transfecting miR-1297 mimics or inhibitor; miR-1297 overexpression or inhibition was confirmed using qRT-PCR. E, F LN-229 cells were transfected with miR-1297 mimics or inhibitor and examined for ADM expression using qRT-PCR and ADM protein levels by Immunoblotting. G Wild- and mutant-type ADM luciferase reporters were constructed as described and co-transfected in 293 T cells with miR-1297 mimics or inhibitor; luciferase activity was determined

Back to article page